<DOC>
	<DOCNO>NCT00002742</DOCNO>
	<brief_summary>RATIONALE : Antifungal therapy liposomal nystatin may reduce fever neutropenia patient undergoing treatment hematologic cancer . It yet know whether liposomal nystatin effective standard amphotericin B treating patient fever neutropenia receive chemotherapy hematologic cancer bone marrow transplantation leukemia . PURPOSE : Randomized phase III trial study effectiveness liposomal nystatin compare standard amphotericin B treat fever neutropenia patient receive chemotherapy hematologic cancer bone marrow transplantation leukemia .</brief_summary>
	<brief_title>Antifungal Therapy Fever Neutropenia Patients Receiving Treatment Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy liposomal nystatin vs standard amphotericin B empiric treatment persistent febrile neutropenic patient . II . Compare incidence drug-related toxicity impairment infusion-related toxicity patient treat liposomal nystatin vs standard amphotericin B. III . Determine pharmacokinetics liposomal nystatin . OUTLINE : Randomized , double-blind study . Arm I : Antifungal Therapy . Liposomal Nystatin . Arm II : Antifungal Therapy . Amphotericin B , NSC-527017 . PROJECTED ACCRUAL : 350 evaluable patient study multicenter trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Amphotericin B , deoxycholate drug combination</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Persistent febrile neutropenia associate 1 follow within 3 month prior entry : Cytotoxic chemotherapy Bone marrow transplantation Neutropenia define either : ANC great 500/mm3 ANC great 1,000/mm3 expect decrease 500/mm3 less within 2 day entry Persistent continuous spike fever least 38 C No association administration pyrogenic substances No response least 72 hour empiric , broadspectrum antibacterial therapy No microbiologically document source infection At least 30 day since document invasive fungal infection PATIENT CHARACTERISTICS : Age : 2 Performance status : Not specify Life expectancy : At least 28 day Hematopoietic : Not specify Hepatic : No grade 2 great hepatic impairment Renal : No grade 2 great renal impairment No peritoneal dialysis hemodialysis Other : No history severe allergic reaction polyene antifungal agent No pregnant nursing woman Negative pregnancy test require fertile woman Effective contraception require fertile woman 3 month study PRIOR CONCURRENT THERAPY : At least 2 week since polyene antifungal therapy Concurrent oral prophylactic antifungal therapy azole antifungal agent ( e.g. , fluconazole , itraconazole ) allow patient remains febrile No concurrent azole therapy At least 30 day since investigational drug device except investigational formulation amphotericin B</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>adult Hodgkin lymphoma</keyword>
	<keyword>adult non-Hodgkin lymphoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>childhood non-Hodgkin lymphoma</keyword>
	<keyword>chronic myeloproliferative disorder</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent adult non-Hodgkin lymphoma</keyword>
	<keyword>infection</keyword>
	<keyword>multiple myeloma plasma cell neoplasm</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>